Background

Fingolimod (FNG) is associated with the development of symptomatic macular edema (ME) in a small subset of multiple sclerosis (MS) patients. By using spectral domain optical coherence tomography (SD-OCT), an increase in the total macular volume (TMV) was rarely detected during the first months of treatment.

Objectives

The objective of this study is to assess whether FNG treatment leads to long-term macular changes in a real-life setting.

Methods

Sixty RRMS patients starting FNG, according to therapeutic indication, were enrolled at three Italian MS centers and followed for 2 years.

Results

The mean TMV did not change between baseline and the follow-up. No patients experienced visual acuity drop during the follow-up.

Conclusions

Initiation of FNG in MS is associated with a modest, not significant, increase in macular volume followed by no further significant changes over 2 years, highlighting the good safety profile of such treatment in MS.

中文翻译：

---

芬戈莫德治疗的多发性硬化症患者的两年黄斑体积评估

背景

芬戈莫德（FNG）与多发性硬化症（MS）的一小部分症状性黄斑水肿（ME）的发展有关。通过使用光谱域光学相干断层扫描（SD-OCT），在治疗的头几个月中很少检测到总黄斑体积（TMV）的增加。

目标

这项研究的目的是评估FNG治疗是否会导致现实生活中的长期黄斑改变。

方法

根据治疗指征，有60名开始FNG的RRMS患者入选了意大利的3个MS中心，并随访了2年。

结果

在基线和随访之间，平均TMV不变。随访期间无患者视力下降。

结论

在MS中开始FNG与黄斑体积的适度（不显着）增加相关，然后在2年内没有进一步的显着变化，突出了此类治疗在MS中的良好安全性。